Three generations tackle diabetes together with the newly available Lantus(R) SoloSTAR(TM) pre-filled insulin pen



    - Convenient, easy-to-use device now available in Canada -

    LAVAL, QC, March 19 /CNW/ - A diagnosis of diabetes often means the
beginning of a life-long struggle to manage glucose (blood sugar) levels. But
for sisters Tina Trotter and Carmen Trudel of Winnipeg, both living with
type 1 diabetes, tackling diabetes together with family makes it a lot easier.
Along with Trudel's nine-year-old son Jonathan and their mother Helen
Compayre, they have started using the newly available pre-filled insulin pen,
Lantus SoloSTAR, as part of their daily diabetes management efforts to achieve
long-term glucose control.
    Lantus SoloSTAR is the first insulin pen available in Canada to come
pre-loaded with a cartridge of Lantus basal insulin, making day-to-day
management of diabetes easier and more convenient for patients living with
type 1 or type 2 diabetes. Lantus is the first and only long-acting insulin to
provide 24-hour glucose-lowering activity with a single daily injection.

    Boosting confidence and providing added convenience for diabetes patients

    Trudel, who is also vision impaired due to her diabetes, says finding the
right insulin gave her more confidence and independence in managing her
diabetes, as well as her son's. "Before starting on Lantus, I had to deal with
sudden drops in my blood sugar, which would make me feel faint and weak. I was
constantly worried about having a low when I was out alone with my dog, and
not being able to find a place to sit down quickly enough," says Trudel.
    "With Lantus SoloSTAR, Jonathan can inject himself, and the pen makes a
clicking noise as he dials up his dose, so I can listen to make sure he has
the right amount," added Trudel. "He's happy with the pen, and anything that
makes it easier for him to live a normal life and play goalie in hockey is a
big relief for me as a mother."
    Lantus SoloSTAR is the only pre-filled insulin pen that allows patients
to administer doses from one to 80 units in one single injection. The pen
offers a 25 per cent greater maximum dosing capacity compared to other insulin
pens. It also incorporates simple, easy-to-read display features, including a
dial and dose setting, as well as numbering that is both large and clear,
lessening the possibility of injection error. In addition, Lantus SoloSTAR
operates with a low injection force, allowing for a gentle injection, often
important for elderly or arthritic patients.
    "I have seen many patients - especially those with type 2 diabetes who
need to start insulin - struggle with their insulin injections, so anything
that makes it easier is great news," said Lori Berard, a diabetes nurse
educator based in Winnipeg who works with Tina, Carmen and their mother. "The
pen provides a more convenient way to take Lantus insulin as there is no need
to load or change insulin cartridges. Its safety features mean it will work
for a broad range of people from the very young to the very old. This gives me
peace of mind that my patients will be able to safely use the device and
follow their treatment plan to control their blood sugar levels."

    An evolution in diabetes treatment

    Trotter says both the Lantus insulin and the Lantus SoloSTAR pen have
made a positive difference in her life as well. "Diabetes has been in our
family for as long as I can remember, and I've seen the changes in diabetes
treatments and devices, from boiling syringes to sterilize them, to the Lantus
SoloSTAR today," she said. "We've come a long way, and I'm glad we're on this
end of the evolution."
    Lantus SoloSTAR recently received the prestigious GOOD DESIGN Award from
the Chicago Athenaeum Museum of Architecture and Design, which praised the
device's combination of sleek, attractive design with advanced, sophisticated
technology that will benefit people living with diabetes.

    The right combination of treatment and delivery

    "The successful management of diabetes means equipping patients with the
essential tools to safely and effectively achieve and sustain control of their
blood sugar levels," said Dr. Amir Hanna, professor in the department of
medicine at the University of Toronto, and staff endocrinologist and deputy
division head of endocrinology and metabolism at St. Michael's Hospital in
Toronto. "Lantus SoloSTAR offers the right combination of a proven,
long-acting insulin and a convenient and easy-to-use delivery system. These
features will better ensure that patients benefit from optimal control of
sugar levels, lower incidence of complications and increased daily
compliance."
    For Arlen Delfosse, a Toronto resident living with type 2 diabetes and a
patient of Dr. Hanna, Lantus SoloSTAR provides this balance, offering both an
effective treatment and a delivery method that fits with his busy, active
lifestyle. He started using Lantus SoloSTAR after the insulin he was using
wasn't providing sufficient control of his blood glucose levels. "Keeping my
blood sugar levels stable means that I can enjoy life more - especially skiing
and cycling, which are my favourite activities," said Delfosse. "I'm still
careful about monitoring my sugar levels, but when I'm doing what I love,
sometimes I even forget that I have diabetes."
    Lantus, launched on the Canadian market in 2005, is the most prescribed
basal insulin in Canada and around the world. The Lantus SoloSTAR pen was
approved by Health Canada in April 2007 and has been commercially available
for the benefit of all Canadian patients since February 2008.

    Diabetes in Canada

    Diabetes is a chronic condition in which the body does not produce or
properly use insulin - the hormone needed to convert glucose (sugar) into
energy. In Canada, more than two million people have diabetes. By the end of
the decade, this number is expected to rise to three million. According to
Health Canada, one-third of adults with diabetes are unaware of their
condition. According to the Canadian Diabetes Association, diabetes and its
complications cost the Canadian healthcare system an estimated $13.2 billion
every year. By 2010, it is estimated that this number will rise to
$15.6 billion a year, and by 2020 to $19.2 billion a year.

    About Lantus(R)

    Lantus is a novel recombinant human insulin approved for once-daily
administration in the treatment of patients over the age of 17 with type 1 or
type 2 diabetes who require basal (long-acting) insulin for the control of
hyperglycemia (abnormally high blood sugar). Lantus is also indicated in the
treatment of pediatric patients with type 1 diabetes.
    Most insulins have a "peak of action", which refers to the time at which
insulin reaches its maximum effect in the body. With Lantus, the insulin is
released into the bloodstream at a relatively constant rate throughout the day
and night; therefore, it has no pronounced peak.

    About sanofi-aventis

    Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York
(NYSE : SNY).
    Sanofi-aventis is represented in Canada by the pharmaceutical company
sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines
company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they
employ more than 2,000 people across the country.

    
    NOTE TO EDITORS:   B-Roll is available at the following times and
                       coordinates:

    DATE OF FEED:      Wednesday, March 19, 2008

    TIME OF FEED:      11:00-11:30 AM EDT and 2:30-3:00 PM EDT

    CO-ORDINATES:      Anik F2 C
                       Transponder 1B
                       Audio subcarrier 6.2 and 6.8
                       Downlink frequency 3740 vertical

    TOC                CFA TX 1
    





For further information:

For further information: or to book an interview with a physician or
patient, please contact: Laura Grice, Manning Selvage & Lee (MS&L), (416)
847-1319, laura.grice@mslpr.ca; Sanofi-aventis, www.sanofi-aventis.com,
Relations Presse: Tél.: (+) 33 1 53 77 44 50, Relations Investisseurs: Tél.:
(+) 33 1 53 77 45 45

Organization Profile

SANOFI-AVENTIS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890